Guidance Pending To Help Clinical Labs Comply With FDA Manufacturing Regs
This article was originally published in The Gray Sheet
Executive Summary
FDA is developing guidance for clinical laboratories on how to comply with the device manufacturing quality system regulation
You may also be interested in...
AdvaMed Wants Across-The-Board Risk-Based Regulation For Diagnostics
Under an AdvaMed plan for expanding FDA regulation of diagnostic tests, tests that consist of new or unproven biomarkers on new technology platforms would likely require a pre-market approval application
Diagnostics In Brief
Pathwork tumor test: Molecular diagnostic firm receives FDA clearance July 29 for its Pathwork Tissue of Origin Test, used to determine the origin of hard-to-identify tumors. The test uses an Affymetrix microarray, cleared along with the tumor test, to measure the uncertain tumor's gene expression pattern and compare it to a panel of 15 known tumor types, including bladder, breast and colorectal. Pathwork is finalizing details to make the IVD kit available later this year; the test is already available as a service through the firm's lab. The test is the second in vitro diagnostic multivariate index assay (IVDMIA) cleared by FDA, after Agendia's MammaPrint breast cancer recurrence test
FDA Genetic Test Oversight Is On The Rise, But How Far Can It Go?
It looks increasingly likely that FDA will play a larger role in genetic test oversight, though policymakers may soon have to decide just how much more the agency can and should do